Evolus EOLS
NASDAQ EOLS
$8.39 +0.04 (+0.48%)
At close: Aug 21, 2026 · 4:00 PM EDT

Evolus (EOLS) Total Non-Current Liabilities (2017 - 2022)

Evolus' (EOLS) quarterly Total Non-Current Liabilities came in at $159.5 million in Q4 2022, up 21.87% YoY from $130.9 million in Q4 2021, and down 2.46% on a QoQ basis from $163.5 million in Q3 2022.

Evolus (EOLS) Total Non-Current Liabilities (2017 - 2022) Analysis & Trends

Evolus (EOLS) has 6 years of Total Non-Current Liabilities data on file, last reported at $159.5 million in Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 21.87% year-over-year to $159.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $159.5 million (up 21.87% YoY) and the FY2022 annual result came in at $159.5 million, up 21.87% from the prior year.
  • Total Non-Current Liabilities retreated to $159.5 million in Q4 2022, from $163.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $240.5 million in Q4 2020 to a low of $34.8 million in Q1 2018.
  • A 5-year average of $116.2 million and a median of $117.3 million in 2020 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2018 — Total Non-Current Liabilities slumped 83.64% — and 2019, when it jumped 225.1%.
  • Tracing EOLS's Total Non-Current Liabilities over 5 years: stood at $37.3 million in 2018, then surged by 212.14% to $116.3 million in 2019, then soared by 106.77% to $240.5 million in 2020, then sank by 45.58% to $130.9 million in 2021, then gained by 21.87% to $159.5 million in 2022.
  • The last three Total Non-Current Liabilities figures came in at $159.5 million (Q4 2022), $163.5 million (Q3 2022), and $164.1 million (Q2 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -13.28 Bn
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn 16.45 Bn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn 11.64 Bn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn 33.50 Bn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn 607.80 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn 18.76 Bn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn 1.37 Bn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn 6.42 Bn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - 334.00 Mn
10 Evolus 552.49 Mn 507.32 Mn 57.18 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 159.48 Mn
Sep 30, 2022 163.50 Mn
Jun 30, 2022 164.06 Mn
Mar 31, 2022 153.41 Mn
Dec 31, 2021 130.87 Mn
Sep 30, 2021 112.82 Mn
Jun 30, 2021 128.73 Mn
Mar 31, 2021 128.91 Mn
Dec 31, 2020 240.48 Mn
Mar 31, 2020 117.33 Mn
Dec 31, 2019 116.30 Mn
Jun 30, 2019 114.43 Mn
Mar 31, 2019 99.67 Mn
Dec 31, 2018 37.26 Mn
Sep 30, 2018 37.31 Mn
Jun 30, 2018 35.20 Mn
Mar 31, 2018 34.81 Mn
Dec 31, 2017 227.78 Mn